drugset
drugset / Trial / NCT03182933

Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty

NCT03182933 ↗

Phase 4 Terminated 64 enrolled University of Wisconsin, Madison
RandomizedParallel-groupTriple-blindTreatment

Summary

Study will evaluate the effect of liposomal bupivacaine versus standard bupivacaine on physical therapy measures and pain scores as well as opiate consumption.

Timeline

Start
2017-05-30
Primary completion
2018-07-16
Completion
2018-07-16

Outcome

Outcome not reported

Stopped: “Terminated due to surgeon preferences”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.5 % Other
Subject Bupivacaine Other / unclassified 1.33 % Other

Indications

No indication recorded.